ストックスクリーナーアプリを入手
1.89
0.53%
0.01
プレマーケット:
1.91
0.02
+1.06%
前日終値:
$1.88
開ける：
$1.85
24時間の取引高:
2.53M
Relative Volume:
0.56
時価総額：
$316.81M
収益：
$250.00K
当期純損益:
$-16.78M
株価収益率:
-1.2729
EPS:
-1.4848
ネットキャッシュフロー:
$-10.85M
1週間 パフォーマンス:
-3.57%
1か月 パフォーマンス:
+4.42%
6か月 パフォーマンス:
+11.18%
1年 パフォーマンス:
+183.10%
1日の値動き範囲:
$1.8101
$1.92
1週間の範囲:
$1.48
$2.00
52週間の値動き範囲:
$0.53
$2.64
Palisade Bio Inc Stock (PALI) Company Profile
名前
Palisade Bio Inc
セクター
電話
(858) 704-4900
住所
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, REGN, ARGX, ALNY, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.89 | 316.81M | 250.00K | -16.78M | -10.85M | -1.4848 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-26 | 開始されました | H.C. Wainwright | Buy |
| 2026-02-25 | 開始されました | Stifel | Buy |
| 2026-01-09 | 開始されました | B. Riley Securities | Buy |
| 2025-12-29 | 開始されました | Piper Sandler | Overweight |
Palisade Bio Inc (PALI) 最新ニュース
Palisade Bio (PALI) reports positive phase 1b data for PALI-2108 in UC patients - MSN
Palisade Bio partners with Iterative Health to advance PALI-2108 - TipRanks
Palisade Bio enters agreement with Iterative Health and completes $3 million stock sale - Investing.com
Palisade Bio raises $3.0M from Iterative Health affiliate to support PALI-2108 Phase 2 enrollment - TradingView
Palisade Bio (NASDAQ: PALI) sells 1.54M shares to Iterative Health affiliate - stocktitan.net
Palisade Bio, Inc. (PALI) stock price, news, quote and history - Yahoo Finance UK
Clear Street Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Edwards Lifesciences (EW) and Palisade Bio (PALI) - The Globe and Mail
Clear Street reiterates Palisade Bio stock rating on trial data By Investing.com - Investing.com South Africa
Update: Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's Disease - moomoo.com
Clear Street reiterates Palisade Bio stock rating on trial data - Investing.com
Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's Disease - marketscreener.com
Palisade Bio Shares Phase 1b PALI-2108 Data Showing Safety, PK and Early Crohn’s Efficacy Signals - MarketBeat
Support Test: Can Palisade Bio Inc beat the S P 500Market Growth Summary & Weekly Momentum Picks - baoquankhu1.vn
Palisade Bio posts trial data for lead asset (PALI:NASDAQ) - Seeking Alpha
Crafting a New Financial Era: Palisade Bio Inc.’s Strategic Moves - StocksToTrade
Palisade Bio stock maintains buy rating at Stifel on trial data - Investing.com Canada
Palisade Bio stock maintains buy rating at Stifel on trial data By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $7 - moomoo.com
Palisade Bio reports Phase 1b trial results for Crohn’s drug By Investing.com - Investing.com South Africa
Palisade Bio reports Phase 1b trial results for Crohn’s drug - Investing.com
After 2 weeks, Palisade’s Crohn’s pill showed no serious side effects - stocktitan.net
HC Wainwright Forecasts Palisade Bio Q1 Earnings - MarketBeat
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
PALI Should I Buy - Intellectia AI
HC Wainwright Begins Coverage on Palisade Bio (NASDAQ:PALI) - marketbeat.com
Big Picture: Can Palisade Bio Inc expand its profit marginsMarket Performance Summary & Free Accurate Trade Setup Notifications - baoquankhu1.vn
PALI SEC FilingsPalisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Palisade Bio: Undervalued Biotech With Blockbuster Potential, Initiating With A Speculative Buy Rating - Seeking Alpha
Palisade Bio 2026 10-K: Clinical Development, Risk Factors, and Precision Medicine Strategies for IBD - Minichart
Aug Spikes: Can Palisade Bio Inc expand its profit marginsQuarterly Earnings Report & Weekly Return Optimization Alerts - baoquankhu1.vn
Palisade Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Palisade Bio (NASDAQ:PALI) Issues Quarterly Earnings Results, Beats Estimates By $1.10 EPS - MarketBeat
Palisade Bio Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Palisade Bio 10-K: Net loss $16.8M, EPS $(0.30) - TradingView
[10-K] PALISADE BIO, INC. Files An... - Stock Titan
Palisade Bio (PALI) Reports Positive Phase 1b Data for PALI-2108 in UC Patients - Insider Monkey
PALI Q4'25 Earnings: revenue estimate is 0 USD - TradingView
Day Trade: Can Palisade Bio Inc beat the S P 500Bear Alert & Stepwise Trade Execution Plans - baoquankhu1.vn
Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Palisade Bio (PALI) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Palisade Bio (PALI) Stock Analysis Report | Financials & Insights - Benzinga Japan
RSI Check: Will Palisade Bio Inc outperform its industry peers2026 Trends & Technical Pattern Recognition Alerts - baoquankhu1.vn
Aug Macro: Can Palisade Bio Inc maintain sales growth2025 Buyback Activity & Safe Capital Preservation Plans - baoquankhu1.vn
Published on: 2026-03-07 13:46:23 - baoquankhu1.vn
US Market Recap: Will Palisade Bio Inc stock recover after earningsTrade Volume Summary & AI Forecast for Swing Trade Picks - baoquankhu1.vn
PALI Earnings History & Surprises | EPS & Revenue Results | PALISADE BIO INC (NASDAQ:PALI) - ChartMill
Treasury Yields: Will Palisade Bio Inc benefit from current market trends2025 Winners & Losers & Community Consensus Trade Signals - baoquankhu1.vn
Palisade Bio Inc (PALI) 財務データ
収益
当期純利益
現金流量
EPS
0.49%
1.47%
大文字化:
|
ボリューム (24 時間):